Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib

201989 citationsJournal Articlegold Open Access

Authors

Haruki Uojima · Shonan Kamakura General Hospital

Makoto Chuma · Yokohama City University Medical Center

Yoshiaki Tanaka · Kitasato University

Hisashi Hidaka · Kitasato University

Takahide Nakazawa · Kitasato University

Shogo Iwabuchi · Yokufukai Hospital

Satoshi Kobayashi ·

Abstract

Decreased skeletal muscle mass is associated with the occurrence of severe AEs and worse TTF and OS. Skeletal muscle mass can be used as a predictive marker for tolerability and prognosis to lenvatinib in patients with HCC.

Topics & Keywords

Nutrition and Health in Aging Liver Disease Diagnosis and Treatment Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Liver Cancer

Volume 9, Issue 2, pp. 193-206

DOI: 10.1159/000504604

Field-Weighted Citation Impact: 5.07